Literature DB >> 2774099

Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. A quantitative immunohistochemical study.

J Smolle1, H P Soyer, H Kerl.   

Abstract

In various tumors, proliferative activity has been demonstrated to be closely related to the degree of malignancy. In the present study, we examined the proliferative pool in a total of 25 melanocytic (nevocytic) skin tumors by immunohistochemical staining with Ki 67 monoclonal antibody (labeling the G1, S, G2-phase of the cell cycle) and quantitative morphological evaluation. There were highly significant differences in the numerical density of Ki 67-positive cells between nevocellular nevi (number of positive cells: 2.2 +/- 0.7 X 10(3)/mm3), primary malignant melanoma (6.3 +/- 1.9 X 10(3)/mm3), and metastatic malignant melanoma (47.0 +/- 9.2 X 10(3)/mm3). Within the malignant melanoma group, there was a significant correlation between proliferative activity and maximum tumor thickness (r = 0.85; p less than 0.05). Comparison with previous studies using tritiated thymidine labeling and colony-forming efficiency shows that the stereological evaluation of Ki 67 staining in melanocytic skin tumors provides a reliable estimate of proliferative activity, which might be of prognostic value.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2774099     DOI: 10.1097/00000372-198908000-00002

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  8 in total

1.  A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology.

Authors:  Kenneth G Linden; Sancy A Leachman; Jonathan S Zager; James G Jakowatz; Jaye L Viner; Christine E McLaren; Ronald J Barr; Philip M Carpenter; Wen-Pin Chen; Craig A Elmets; Joseph A Tangrea; Sung-Jig Lim; Alistair J Cochran; Frank L Meyskens
Journal:  Cancer Prev Res (Phila)       Date:  2014-03-10

2.  Proliferative activity of keratinocytes correlates with that of melanocytes in naevi and melanomas.

Authors:  M Tronnier; R Kämmerer; H H Wolff
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

3.  Factor XIIIa-positive dendrocytes and proliferative activity of cutaneous cancers.

Authors:  C Piérard-Franchimont; J E Arrese; A F Nikkels; W al-Saleh; P Delvenne; G E Piérard
Journal:  Virchows Arch       Date:  1996-09       Impact factor: 4.064

4.  Bcl-2 expression in human melanocytes and melanocytic tumors.

Authors:  J J van den Oord; N Vandeghinste; M De Ley; C De Wolf-Peeters
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

Review 5.  Investigation of cAMP microdomains as a path to novel cancer diagnostics.

Authors:  Garrett Desman; Caren Waintraub; Jonathan H Zippin
Journal:  Biochim Biophys Acta       Date:  2014-09-07

6.  Proliferative activity of cutaneous melanocytic neoplasms defined by a proliferating cell nuclear antigen labelling index.

Authors:  Y Tokuda; K Mukai; Y Matsuno; S Furuya; Y Shimosato; Y Takasaki; T Saida; K Ishihara
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

7.  Proliferative activity of primary cutaneous melanocytic tumours.

Authors:  T Kuwata; M Kitagawa; T Kasuga
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Lysosome-mediated processing of chromatin in senescence.

Authors:  Andre Ivanov; Jeff Pawlikowski; Indrani Manoharan; John van Tuyn; David M Nelson; Taranjit Singh Rai; Parisha P Shah; Graeme Hewitt; Viktor I Korolchuk; Joao F Passos; Hong Wu; Shelley L Berger; Peter D Adams
Journal:  J Cell Biol       Date:  2013-07-01       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.